WW · Ww International, Inc.
Price & Indicators
Up next
Metrics snapshot
Useful current figures from the complete screener profile.
AI Brief
Q2 FY26 earnings call · Aug 5, 2026TL;DR. WW reaffirmed full-year 2026 guidance and posted Q2 Clinical subscription revenue growth of 30.4% with Clinical subscribers up 55.7% YoY, while total revenue declined 14.2% to $162.3 million as Behavioral subscription revenue fell 22.7% and behavioral end-of-period subscribers dropped 24.6% YoY.
- + Clinical subscription revenue grew 30.4% to $39.9 million and clinical end-of-period subscribers rose 55.7% YoY to 197,000
- + Core+ subscribers reached 541,000, up 13.9% YoY, marking the third consecutive quarter of sequential growth in the higher-value behavioral tier
- + ARPU rose 10.2% YoY and adjusted gross margin held at a near-record 73.6% despite the mix shift toward clinical
- − Total Q2 revenue declined 14.2% YoY to $162.3 million from $189.2 million
- − Behavioral subscription revenue fell 22.7% YoY to $121.5 million and behavioral end-of-period subscribers declined 24.6% YoY to 2.3 million
- − Adjusted EBITDA of $39.8 million was well below the $65.3 million in the prior-year quarter
AI-generated from the earnings call and 8-K · may contain errors · not investment advice
Equibles Rating
blended score · not investment adviceBlended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders BuyIllustrative technical + ownership context — a signal mix, not investment advice.
Versus peers
Medical Care Facilities — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
WW
this stock
Ww International, Inc.
|
$172.23M | -44.3% | +12.2% | — | 16.6% |
|
HCA
HCA Healthcare, Inc.
|
$91.98B | -11.4% | +7.1% | 14.3 | 2.8% |
|
FSNUY
Fresenius SE & Co. KGaA
|
$29.36B | -9.5% | — | — | 0.0% |
|
THC
Tenet Healthcare Corp
|
$21.06B | +33.8% | +0.9% | 10.1 | 3.1% |
|
FMS
Fresenius Medical Care AG
|
$12.11B | -4.5% | +5.9% | — | 0.5% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionPerformance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| WW | -7.8% | -1.5% | -27.3% | -2.5% | -44.3% |
| SPY | -0.5% | -1.2% | +12.6% | -0.7% | +11.7% |
| vs SPY | -7.3% | -0.3% | -39.9% | -1.8% | -56.0% |
Capital returns
Dividends per share over the trailing 365 days by ex-date · buyback figures as last reported in SEC filings ("spent" derived as authorized − remaining; when several programs run concurrently, authorized is their combined total per the newest filing) · components shown separately — trailing-year buyback spend isn't tracked, so no combined shareholder yield is derived.